Trial Condition(s):

Prostate Cancer, Castration resistant

Multi-academic center study of Xofigo patients

Bayer Identifier:

19863 Identifier:


EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival (OS) associated with treatment sequences involving radium-223 and chemotherapy. While clinical trials of radium-223 has demonstrated a survival benefit in the treatment of mCRPC, both pre and post- docetaxel, study lacked exposure to second generation androgens and hence could not assess outcomes pre or post abiraterone or enzalutamide.
The specific objective of this study is to describe and compare the clinical outcomes between treatment sequences for patients with mCRPC where 1) radium-223 is used (alone or in combination with abiraterone or enzalutamide) prior to chemotherapy versus 2) radium-223 used after chemotherapy in the treatment of mCRPC. The secondary objectives are to describe the safety patterns of docetaxel use among mCRPC patients who received chemotherapy post radium-223.

Inclusion Criteria
- Received at least one dose of radium-223 after mCRPC diagnosis 
- Received at least one prescription or dose of chemotherapy for treatment of mCRPC
Exclusion Criteria
- No documented visceral metastasis at initiation of radium-223

Trial Summary

Enrollment Goal
Trial Dates
Could I receive a placebo?
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers

Where to Participate


Bayer US

Whippany, United States, 07981

Trial Design